Ine M.
- Country
- Belgium
- Department
- Hematologie
Research Overview
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax and Azacitidine in Treatment-Naïve Acute Myeloid Leukemia Ineligible for Standard Induction Therapy
- Randomized, Double-Blind, Event-Driven Trial of Posaconazole vs. Fluconazole for Antifungal Prophylaxis in Acute Myeloid Leukemia Patients
- HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Data & Insights
Has run more than one trial at 103 of 173 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating acute myeloid leukemia (AML), with particular focus on developing treatment strategies for patients who cannot receive standard induction therapy.
- Blood Cancer Therapeutics
- Novel Combination Treatments
- Treatment-Naïve Patient Care
Their research explores innovative therapeutic approaches using targeted agents in combination with established treatments for hematologic malignancies.
Treatment Development
The investigator's work centers on evaluating combination therapy approaches for patients with blood cancers, particularly focusing on survival outcomes and remission rates.
- Alternative Treatment Protocols
- Remission Assessment
- Patient-Specific Approaches
Their expertise includes developing treatment protocols for patients who require alternatives to conventional therapy methods.
Clinical Innovation
The investigator focuses on advancing therapeutic strategies for previously untreated blood cancer patients, with emphasis on improving survival outcomes.
- Treatment Response Assessment
- Therapeutic Innovation
- Patient Safety Protocols
Their work encompasses evaluating novel therapeutic combinations for optimal treatment outcomes in hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
